FUTURE PLANS

For details of our future plans, see "Business — Our Strategies."

USE OF [REDACTED]

The table below sets forth the estimated net [**REDACTED**] of the [**REDACTED**] which we will receive after deduction of [**REDACTED**] fees and commissions and estimated expenses payable by us in connection with the [**REDACTED**] (assuming the [**REDACTED**] and the [**REDACTED**] is not exercised):

Assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**] (being the low point of the [**REDACTED**] range stated in this Document)	HK$[**REDACTED**] million
Assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**] (being the mid point of the [**REDACTED**] range stated in this Document)	HK$[**REDACTED**] million
Assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**] (being the high point of the [**REDACTED**] range stated in this Document)	HK$[**REDACTED**] million

We intend to use the net [**REDACTED**] for the following purposes (based on the mid-point of the [**REDACTED**] range stated in this Document):

- Approximately [**REDACTED**]% (or HK$[**REDACTED**] million) is expected to be allocated to the R&D and commercialization of our Core Product. In particular:

  (i) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) is expected to be allocated to the R&D of RC120 in China, primarily with respect to the expansion of indication in adult abdominal solid organs puncture surgery and certain new functions including dynamic respiratory motion compensation, and AI-assisted 3D reconstruction and surgery path planning functions. We will use the [**REDACTED**] for the R&D and production cost of test prototypes, R&D staff cost, and the application for registration with the NMPA;

  (ii) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) is expected to be allocated to the R&D, clinical studies and registration filings of RC120 in selected jurisdictions outside of China, such as the United States, Europe and certain countries in Southeast Asia. We plan to obtain FDA approval by 2029 and obtain CE certification by 2030. In Southeast Asian market, we plan to register our product in Indonesia and Malaysia first and to obtain approval by 2030;

(iii) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) is expected to be allocated to the marketing, sales expansion and other promotion initiatives of our RC120 in China, in order to expand sales channels, broaden our market coverage and increase market penetration. Specific measures may include participating in and/or organizing industry trade exhibitions, academic conferences, conducting sales promotion activities, customer demonstrations and order maintenance efforts. We will also hold product training and clinical department education programs, such as on-site clinical training. These initiatives are intended to enhance market awareness of RC120, strengthen cooperative relationships with healthcare service institutions and clinical professionals, and support the expansion of our sales network to further penetrate the target markets; and

(iv) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) is expected to be allocated to the sales and marketing activities and commercialization of RC120 in overseas markets. We plan to actively participate in relevant overseas industry exhibitions to showcase and promote our products to potential customers. Additionally, we intend to establish our clinical team overseas. This clinical team will be responsible for conducting localized clinical demonstrations, providing professional technical support for overseas medical institutions, and facilitating academic exchanges with local medical professionals, thereby enhancing the recognition and adoption of our products in international markets.

- Approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be allocated to the R&D and commercialization of our other product candidates in addition to the Core Product. Specifically:

(i) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be allocated to the R&D and production of test prototypes, clinical studies and registration filings of certain consumables to be used in puncture surgeries, including both passive consumables (e.g., disposable puncture needle and puncture guide) and active consumables (e.g., ablation needles);

(ii) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be allocated to the R&D and production of test prototypes, clinical studies and registration filings of our spinal surgery navigation and positioning system product candidate. This platform is designed for spinal screw placement surgeries. We have initiated pre-clinical studies and expect to obtain the NMPA's approval in 2031; and

(iii) approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be allocated to the R&D and production of test prototypes, clinical studies and registration filings of our RC100 and CT integrated puncture surgery navigation and positioning system product candidates. We have initiated pre-clinical studies and expect to obtain the NMPA's approval in 2031 for CT integrated puncture surgery navigation and positioning system, and in 2027 for RC100.

- Approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be allocated to enhance our manufacturing facilities, mainly including the increase of more production workshops, investment in production equipment, and employment of more production staff;

- Approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be allocated to external authorization and cooperation for certain surgical consumables; and

- Approximately [**REDACTED**]% (or HK$[**REDACTED**] million) will be used for our working capital and general corporate purposes.

If the [**REDACTED**] is set at the high point or the low point of the [**REDACTED**] range (assuming the [**REDACTED**] and the [**REDACTED**] is not exercised), the net [**REDACTED**] will increase or decrease by approximately HK$[**REDACTED**] million (after deducting the [**REDACTED**] fees and expenses in relation to the [**REDACTED**]). We intend to apply the additional or reduced net [**REDACTED**] to the above purposes on a pro-rata basis.

The net [**REDACTED**] that we would receive if the [**REDACTED**] and the [**REDACTED**] were exercised in full would be (i) HK$[**REDACTED**] million (assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**], being the Minimum [**REDACTED**]), (ii) HK$[**REDACTED**] million (assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**], being the mid-point of the [**REDACTED**] range) and (iii) HK$[**REDACTED**] million (assuming an [**REDACTED**] of HK$[**REDACTED**] per [**REDACTED**], being the Maximum [**REDACTED**]).

If the net [**REDACTED**] of the [**REDACTED**] are not immediately applied to the above purposes, we will only deposit the [**REDACTED**] from the [**REDACTED**] into short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions in Hong Kong or the PRC (as defined under the SFO) in circumstances permitted by relevant laws and regulations. We will issue an appropriate announcement if there is any material change to the above proposed use of [**REDACTED**].